ARTICLE | Company News
NICE now backs Pfizer's Inlyta for second-line RCC
March 5, 2014 1:08 AM UTC
The U.K.'s NICE reversed a prior decision and now recommends Inlyta axitinib from Pfizer Inc. (NYSE:PFE) to treat advanced renal cell carcinoma (RCC) in patients who failed treatment with a first-line...